Drug intelligence / Profile preview

HT-030

Development stage: Preclinical
Lead developer: Hinge Therapeutics
Modality: Small Molecules
Administration: Injectable

Overview

**HT-030** is a preclinical injectable repurposed small-molecule program from Hinge Therapeutics for **hemophilia A, hemophilia B, and other bleeding disorders**. The program is directed against **antithrombin**, with the intended pharmacology inferred to be **functional inhibition or negative modulation of antithrombin** in order to rebalance thrombin generation and improve hemostasis in factor-deficient bleeding disorders. Based on the company pipeline, HT-030 is Hinge Therapeutics' most advanced hemophilia program and is currently in **lead optimization**.

Targets

ATIII (Antithrombin III)

Beyond the preview

Go deeper on HT-030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT-030.

Explore the full profile